Vascular risk factors in sudden hearing loss

Thrombosis and Haemostasis

Volumn 95, Issue 3, 2006, Pages 454-461

  Rudack, Claudia ^a   Langer, Claus ^a   Stoll, Wolfgang ^a   Rust, Stephen ^a   Walter, Michael ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Fibrinogen fibrin; Gene mutations; Lipid mediators; Platelet physiology; Thrombophilia

Indexed keywords

ALPHA2 INTEGRIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGED; ALLELE; APHERESIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HYPERCHOLESTEROLEMIA; HYPOALPHALIPOPROTEINEMIA; HYPOLIPOPROTEINEMIA; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SUDDEN DEAFNESS;

EID: 33645553588     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-08-0554     Document Type: Article

References (50)

1. Nakashima T, Itoh A, Misawa H, et al. Clinicoepidemologic features of sudden deafness diagnosed and treated at university hospitals in Japan. Otolaryngol Head Neck Surg 2000; 123: 593-7.
2. Yanagita N, Nakashima T, Ohno Y, et al. Estimated annual number of patients treated for sensorineural hearing loss in Japan. Results of a nationwide epidemiological survey in 1987. Acta Otolaryngol Suppl 1994; 514: 9-13.
3. Olzowy B, Osterkorn D, Suckfull M. The incidence of sensoneurinal sudden hearing loss is greater than previously presumed. MMW Fortschr Med 2005; 147: 37-8.
4. Klemm E, Flach M. Sudden deafness. A clinical analysis with special reference to tympanoscopy. Laryngorhinootologie 1991; 70: 646-9.
5. Stokroos RJ, Albers FW, Schirm J. The etiology of idiopathic sudden sensorineural hearing loss. Experimental herpes simplex virus infection of the inner ear. Am J Otol 1998; 19: 447-52.
6. Wilson WR, Veltri RW, Laird N, et al. Viral and epidemiologic studies of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 1983; 91: 653-8.
7. Suckfull M. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 2002; 360: 1811-7.
8. Suckfull M. Heparin-induced extracorporeal lowdensity lipoprotein precipitation apheresis: a new therapeutic concept in the treatment of sudden hearing loss. Ther Apher 2001; 5: 377-83.
9. Ullrich H, Kleinjung T, Steffens T, et al. Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis. J Clin Apheresis 2004; 19: 71-8.
10. Franco F. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haemotol 2001; 115: 491-506.
11. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
12. Maresca G, Di Blasio A, Marchioli R, et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-77.
13. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211-6.
14. Nofer JR, Tepel M, Kehrel B, et al. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation 1997; 95: 1370-7.
15. Surya I, Akkerman J-W. The influence of lipoproteins on blood platelets. Am Heart J 1993; 125: 272-5.
16. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
17. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33: 357-421.
18. Curran JM, Fatah-Ardalani K, Tornvall P, et al. A hypothesis to explain the reported association of the a-fibrinogen A312 allele with thromboembolic disease. Thromb Haemost 2001; 85: 1122-3.
19. Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr3l2Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-6.
20. Curran JM, Evans A, Arveiler D, et al. The a fibrinogen T/A312 polymorphism in the ECTIM study. Thromb Haemost 1998; 79: 1057-8.
21. Humphries SE, Cook M, Dubowitz M, et al. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1: 1452-5.
22. Heinrich J, Funke H, Rust S, et al. Impact of polymorphisms in the a- and β-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. Thromb Res 1995; 77: 209-15.
23. Zito F, Di Castelnuovo A, Amore C, et al. Bcl I polymorphism in the fibrinogen β-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol 1997; 17: 3489-94.
24. Rudack C, Langer C, Junker R. Platelet GPIaC807T polymorphism is associated with negative outcome of sudden hearing loss. Hear Res 2004; 191: 41-8.
25. Michel O, Jahns T, Joost-Enneking M, et al. The Stennert antiphlogistic-rheologic infusion schema in treatment of cochleovestibular disorders. HNO 2000; 48: 182-8.
26. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733-7.
27. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-5.
28. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993; 21: 3623-9.
29. Staatz WD, Walsh JJ, Pexton T, et al. The a2βI integrin cell surface collagen receptor binds to the a 1 (I)CB3 peptide of collagen. J Biol Chem 1990; 265: 4778-81.
30. Reiner AP, Kumar PN, Schwartz SM, et al. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000; 31: 1628-33.
31. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-4.
32. Roest M, Banga JD, Grobbee DE, et al. Homozygosity for 807 T polymorphism in a(2) subunit of platelet a(2)β(1) is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000; 102: 1645-50.
33. Carlsson LE, Santoso S, Spitzer C, et al. The a2 gene coding sequence T807/A873 of the platelet collagen receptor integrin a2β1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-6.
34. Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002; 22: 14-20.
35. Santoso S, Kunicki TJ, Kroll H, et al. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449-53.
36. Nagahara K, Fisch U, Yagi N. Perilymph oxygenation in sudden and progressive sensorineural hearing loss. Acta Otolaryngol 1983; 96: 57-68.
37. Schuknecht HF, Kimura RS, Naufal PM. The pathology of sudden deafness. Acta Otolaryngol 1973; 76: 75-97.
38. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54: 321-41.
39. Walter M, Reinecke H, Nofer JR, et al. HDL3 stimulates multiple signaling pathways in human skin fibroblasts. Arterioscler Thromb Vasc Biol 1995; 15: 1975-86.
40. Nofer JR, Walter M, Kehrel B, et al. HDL3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. Biochem Biophys Res Commun 1995; 207: 148-54.
41. Walter M, Reinecke H, Gerdes U, et al. Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms. J Clin Invest 1996; 98: 2315-23.
42. Nofer JR, Walter M, Kehrel B, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998; 18: 861-9.
43. Pletscher A, Ferracin F, Block H. HDL, a partial agonist of platelet activation? Thromb Res 1990; 60: 431-2.
44. Lisman T, Weeterings C, de Groot PG. Platelet aggregation: involvement of thrombin and fibrin(ogen). Front Biosci 2005; 10: 2504-17.
45. Gulledge AA, McShea C, Schwartz T, et al. Effects of hyperfibrinogenemia on vasculature of C57BL/6 mice with and without atherogenic diet. Arterioscler Thromb Vasc Biol 2003; 23: 130-5.
46. Benze G, Heinrich J, Schulte H, et al. Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J 2002; 23: 325-30.
47. George JN. Platelets. Lancet 2000; 355: 1531-9.
48. Rozalski M, Nocuj M, Watala C. Adenosine diphosphate receptors on blood platelets - potential new targets for antiplatelet therapy. Acta Biochim Pol 2005, 52: 411-5.
49. Gratton MA, Schulte BA. Alterations in microvasculature are associated with atrophy of the stria vascularis in quiet-aged gerbils. Hear Res 1995; 82: 44-52.
50. Guitton MJ, Casten J, Ruel J, et al. Salicylate induces tinnitus through activation of cochlear NMDA receptors. J Neurosci 2003; 23: 3944-52.